These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 7853968)
1. Enzyme replacement therapy in type 1 and type 3 Gaucher's disease. Zimran A; Elstein D; Abrahamov A Lancet; 1995 Feb; 345(8947):451-2. PubMed ID: 7853968 [No Abstract] [Full Text] [Related]
2. [Enzyme therapy of Gaucher's disease]. Beck M Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225 [No Abstract] [Full Text] [Related]
3. Treatment of Gaucher's disease. Barton NW; Brady RO; Dambrosia JM N Engl J Med; 1993 May; 328(21):1564-5; author reply 1567-8. PubMed ID: 8479496 [No Abstract] [Full Text] [Related]
4. Low-dose versus high-frequency regimens in Gaucher's disease. Hollak CE; Goudsmit R; van Oers MH Lancet; 1996 Feb; 347(8998):406-7. PubMed ID: 8598739 [No Abstract] [Full Text] [Related]
5. Low-dose versus high-frequency regimens in Gaucher's disease. MarĂ³di L Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855 [No Abstract] [Full Text] [Related]
6. Neurological features in Gaucher's disease during enzyme replacement therapy. Ono H; Fujiwara M; Ito K; Ueda H; Mizoguchi N; Sakura N Acta Paediatr; 2001 Feb; 90(2):229-31. PubMed ID: 11236058 [TBL] [Abstract][Full Text] [Related]
7. Treatment regimens in Gaucher's disease. Beutler E Lancet; 1995 Aug; 346(8974):581-2. PubMed ID: 7658807 [No Abstract] [Full Text] [Related]
9. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Zimran A; Elstein D; Levy-Lahad E; Zevin S; Hadas-Halpern I; Bar-Ziv Y; Foldes J; Schwartz AJ; Abrahamov A Lancet; 1995 Jun; 345(8963):1479-80. PubMed ID: 7769903 [TBL] [Abstract][Full Text] [Related]
10. Imiglucerase and its use for the treatment of Gaucher's disease. Weinreb NJ Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336 [TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and therapy of Gaucher disease]. Ehlen C; Heintges T; Niederau C Med Klin (Munich); 1995 May; 90(5):284-90. PubMed ID: 7791695 [TBL] [Abstract][Full Text] [Related]
12. Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro. Dale GL; Kuhl W; Beutler E Proc Natl Acad Sci U S A; 1979 Jan; 76(1):473-5. PubMed ID: 284362 [TBL] [Abstract][Full Text] [Related]
13. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902 [TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase. Dale GL; Beutler E Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4672-4. PubMed ID: 1070017 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Gaucher's disease. Hollak CE; Aerts JM; van Oers MH N Engl J Med; 1993 May; 328(21):1565-6; author reply 1567. PubMed ID: 8479498 [No Abstract] [Full Text] [Related]
16. Alglucerase. A review of its therapeutic use in Gaucher's disease. Whittington R; Goa KL Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912 [TBL] [Abstract][Full Text] [Related]
17. Cerebroside-beta-glucosidase encapsulation in liposomes for Gaucher's disease treatment revisited. Korablyov V; Zimran A; Barenholz Y Pharm Res; 1999 Mar; 16(3):466-9. PubMed ID: 10213382 [No Abstract] [Full Text] [Related]
18. Ceredase dosing concerns for Gaucher's disease. Moscicki RA; van Heek J Am J Med; 1994 Oct; 97(4):402-3. PubMed ID: 7942949 [No Abstract] [Full Text] [Related]
19. A less costly regimen of alglucerase to treat Gaucher's disease. Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900 [TBL] [Abstract][Full Text] [Related]